Back to Search Start Over

Alnylam Pharmaceuticals declares positive Phase 1 results for ALN-APP in Alzheimer's disease study

Source :
M2 Pharma. July 17, 2023
Publication Year :
2023

Abstract

M2 PHARMA-July 17, 2023-Alnylam Pharmaceuticals declares positive Phase 1 results for ALN-APP in Alzheimer's disease study (C)2023 M2 COMMUNICATIONS RNAi therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq: ALNY) on Monday announced [...]

Subjects

Subjects :
Alnylam Pharmaceuticals Inc. -- Product development
Regeneron Pharmaceuticals Inc. -- Product development
Aluminum compounds -- Product development
Amyloid beta-protein -- Research
Alzheimer's disease -- Care and treatment -- Research
Chemistry

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.757390249

Tools

Authors Abstract Subjects Details